Rare-Earth-Catalyzed C–H Bond Addition of Pyridines to Olefins
摘要:
An efficient and general protocol for the ortho-alkylation of pyridines via C-H addition to olefins has been developed, using cationic half-sandwich rare-earth catalysts, which provides an atom-economical method for the synthesis of alkylated pyridine derivatives. A wide range of pyridine and olefin substrates including alpha-olefins, styrenes, and conjugated dienes are compatible with the catalysts.
[EN] ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS<br/>[FR] DÉRIVÉS ACYLSULFONAMIDE POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES ASSOCIÉS À LA SÉNESCENCE
申请人:UNITY BIOTECHNOLOGY INC
公开号:WO2017101851A1
公开(公告)日:2017-06-22
Compounds represented by Formula (I) and (II) and salts thereof are described herein. The compounds or salts of Formula (I) and (II) may be used to treat senescence-associated diseases and disorders.
[EN] NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS D'AZÉTIDINE, COMPOSITIONS PHARMACEUTIQUES CORRESPONDANTES ET LEURS UTILISATIONS
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2013098373A1
公开(公告)日:2013-07-04
The invention relates to new azetidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
[EN] NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] NOUVEAUX DÉRIVÉS HÉTÉROAROMATIQUES ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE
申请人:ADDEX PHARMACEUTICALS SA
公开号:WO2009010455A2
公开(公告)日:2009-01-22
The present invention relates to novel compounds of Formula (I), wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4, M1, M2, M3, Am and Bn are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtype 4 ('mGluR4') which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.